New hope for colorectal cancer: drug duo aims to wipe out hidden tumor DNA
NCT ID NCT05343013
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding celecoxib to TAS-102 can clear tiny amounts of cancer DNA (ctDNA) in the blood of colorectal cancer patients who have finished standard chemotherapy. About 25 adults with stage II-IV colorectal cancer and no visible tumors on scans will take TAS-102 with or without celecoxib for 6 months. The goal is to see if the combination can eliminate these leftover cancer signals and reduce the risk of the cancer coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?